intravitreal injection

Aflibercept rivals laser for diabetic retinopathyIntravitreal aflibercept worked better than panretinal photocoagulation (PRP) for proliferative diabetic retinopathy (PDR) in a new head-to-head trial, according to researchers.
Nailing intravitreal implant injections
Nailing intravitreal implant injectionsTreating diabetic macular edema (DME) has evolved from the ETDRS-style focal/grid laser being the standard of care since 1985 to the modern era of pharmacotherapy—with anti-vascular endothelial growth factor (VEGF) injections now taking center stage as primary treatment for most patients.
Ethics involved in using anti-VEGFs for pediatric patientsParents must be given a full understanding of the treatment risks and potential alternatives in pediatric ROP cases.
Integrin peptide yields positive outcomes for VMA, VMT in phase II trialA new possible therapy for vitreomacular adhesion and vitreomacular traction had positive results in a phase II trial.
Bone marrow cells show promise in degenerative, ischemic retinal diseasesThe safety and feasibility of intravitreal autologous CD34+ bone marrow cells as a potential therapy for retinal disease were evaluated in a pilot study. Preliminary findings demonstrated the treatment was feasible and researchers intend to pursue a larger, prospective study with longer follow-up.
Best practices for injection protocolsNo doubt, my retina colleagues are way ahead of me in considering this issue. Reducing the frequency of injections by developing longer-lasting therapeutic agents and reducing the per-injection risk by careful scrutiny of evidence to determine the best practice when it comes to injection protocols are two possibilities.
Real-world experience provides clarity to intravitreal injection misconceptionUsing real-world experience, a retinal surgeon highlights the optimal settings for use of steroid implants for treatment of diabetic macular edema.